Latest Ibritumomab tiuxetan Stories
SEATTLE, June 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
Molecular imaging is leading to more individualized and effective treatment for non-Hodgkinâ€™s lymphoma by providing a map to guide the path of therapy.
SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SEATTLE, Dec. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. of St.
NEW YORK, Nov.
SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr.
SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SEATTLE, June 22 /PRNewswire-FirstCall/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups Additional Clinical Studies Also Highlighted at Pan Pacific Conference Randomized phase III; PIX 302-Pixantrone plus rituximab significantly improves CR rate (35% vs.
- Afinitor significantly reduced tumor size by 50% or more in one out of three patients with refractory or relapsed lymphoma - Phase III study underway to explore potential of Afinitor to prevent relapse in patients with the most common type of non-Hodgkin's lymphoma EAST HANOVER, N.J., June 8 /PRNewswire/ -- New data show that Afinitor(R) (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease(1).
Pixantrone Named-Patient Program Initiated in Europe SEATTLE, May 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported recent accomplishments and financial results for the quarter ended March 31, 2009.
- The practice of two or more parties jointly purchasing all or part of a butchered cow and dividing the meat between them.